Skip to content
HowShorted

Allogene Therapeutics, Inc. short interest in 2023

In 2023, Allogene Therapeutics, Inc.'s disclosed short interest ran from 23.69% of shares outstanding on 13 Jan 2023 to 18.61% on 29 Dec 2023, a change of -5.08 percentage points. The year's high was 28.59% on 14 Apr 2023 and its low 18.33% on 13 Oct 2023, averaging 23.44% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 29.10 days on 15 Feb 2023. Full history: Allogene Therapeutics, Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for Allogene Therapeutics, Inc. in 2023

2023 in figures

Start of year
23.69% (13 Jan 2023)
End of year
18.61% (29 Dec 2023)
Change
-5.08 pp
High
28.59% (14 Apr 2023)
Low
18.33% (13 Oct 2023)
Average
23.44%
Highest days to cover
29.10 (15 Feb 2023)
SEC filings marked
8

Every report in 2023

Allogene Therapeutics, Inc. short interest in 2023
SettlementShort interestDays to coverFilings since previous
13 Jan 202323.69%15.87
31 Jan 202323.86%17.61
15 Feb 202324.37%29.10
28 Feb 202325.56%20.3810-K filed, results (8-K)
15 Mar 202327.60%15.59
31 Mar 202328.44%25.73
14 Apr 202328.59%25.46
28 Apr 202328.19%17.75
15 May 202327.83%16.1210-Q filed, results (8-K)
31 May 202327.45%23.11
15 Jun 202325.75%16.85
30 Jun 202326.18%6.58
14 Jul 202328.29%19.79
31 Jul 202322.62%24.11
15 Aug 202319.55%12.0910-Q filed, results (8-K)
31 Aug 202319.15%24.08
15 Sep 202319.93%15.95
29 Sep 202320.36%23.55
13 Oct 202318.33%23.48
31 Oct 202320.22%27.90
15 Nov 202319.22%12.4710-Q filed, results (8-K)
30 Nov 202318.93%14.09
15 Dec 202319.94%8.34
29 Dec 202318.61%11.19

See also: Allogene Therapeutics, Inc.'s full history · most shorted US stocks of 2023 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.